🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Bordeaux
NCT07119970 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF) * JAK2V617F mutation with an allelic burden greater than 1% * High risk of thrombosis (age over 60 years or prior thrombotic event) * Diagnosis of MPN within the last 12 months * Enrollment in the AVAJAK clinical trial and the FIMBANK biobank * Affiliation with social security * Signed informed consent Exclusion Criteria: * Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min) * Patients under legal protection (guardianship or curatorship) * Patients under heparin treatment at inclusion
💊

What it tests

  • Additional blood sampling
📍

Where

15 sites
CHU d'Angers, Service des maladies du Sang
Angers, France
CH de la Côte Basque, Service Hématologie
Bayonne, France
CHU de Bordeaux, Service Hématologie Biologique
Bordeaux, France
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Bordeaux, France
CHU de Brest, Service Hématologie et Hémostase Clinique
Brest, France
APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire
Créteil, France
CHD de Vendée, Service Onco-hématologie
La Roche-sur-Yon, France
APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire
Le Kremlin-Bicêtre, France

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy